Trial Profile
A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Rigosertib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Hairy cell leukaemia; Lymphoma; Mantle-cell lymphoma; Multiple myeloma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions